Daytime sleepiness (hypersomnia) is a common and serious complaint, although it is less common than insomnia. In a recent community survey in the United States (in Newhaven, Baltimore, St Louis, Durham, and Los Angeles) 102% of the sample at the time of the interview described insomnia, and 3-2% described hypersomnia. Those most affected were young and unemployed people. The complaint of excessive daytime sleepiness includes inappropriate and undesirable sleep during waking hours; reduced motor and cognitive performance; unavoidable napping; sometimes-but not always-an increase in total 24 hour sleep time; and occasionally states of incomplete arousal with automatic behaviour and sleep drunkenness, slufted speech, impaired motor control, and difficulty in focusing. The disability caused by severe daytime sleepiness is comparable with that of severe epilepsy. Many hypersomniac patients are labelled dull, lazy, workshy, or stupid, and if they need treatment are considered to be drug addicts. They have considerable problems at school, work, and home. Daytime sleepiness is an important cause ofindustrial and road traffic accidents. Gaps of several years between the start of symptoms and the achievement of a definite diagnosis ofthe cause of the sleepiness are common. The three common causes of excessive daytime sleepiness are obstructive sleep apnoea (which is dealt with in a separate article), the narcoleptic syndrome, and idiopathic hypersomnia.
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The are essential. The patient usually feels undertreated, but this avoids side * Treatment is just as necessary for effects and it is usually possible to compromise. The dose should not be them as it is for patients with increased unless tolerance develops. Tolerance may be treated by diabetes or epilepsy withdrawal of drugs for 10-14 days, or by 3-6 month rotations of drugs. Doses higher than dexamphetamine 60 mg/day, methylphenidate 100 mg/ day, or mazindol 10 mg/day should be avoided and it should be possible to control nacrolepsy with lower doses.
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Ifmisuse ofdrugs is suspected, a plasma or urinary drug screen is indicated. Particular caution should be exercised when prescribing for' young and elderly patients, and for those with personality disorders and bipolar depressive illnesses.
A simple sleep log with mood, alertness, and behavioural self rating scales during the first three months of treatment helps to monitor treatment. Changes in lifestyle and behaviour will also help.
For patients who wish to drive it is sensible to assess response over a six month period before considering issuing a provisional licence. 
